Iacs-15509
WebbBBP-398 (Formerly known as IACS-15509) Description. A first-in-human study to evaluate the safety, tolerability and maximum tolerated dose (MTD) and establish the recommended phase 2 dose (RP2D) of BBP-398, a SHP2 inhibitor, in patients with advanced solid tumors. Resources and Links. WebbBBP-398 (Formerly Known as IACS-15509) for Solid Tumors BBP-398 with nivolumab for Non-Small Cell Lung Cancer TAS2940 for Breast Cancer ZX-4081 for Advanced Solid Tumors SPYK04 for Metastatic or Locally Advanced Solid Tumors TP-1287 for Sarcoma ABX196 for Hepatocellular Carcinoma 4D-310 for Fabry Disease T3011 + …
Iacs-15509
Did you know?
WebbA Phase 1/1B First-in-Human Study of the SHP2 Inhibitor BBP-398 (Formerly Known as IACS-15509) in Patients With Advanced Solid Tumors : Secondary IDs: Study Status. Record Verification: November 2024 : Overall Status: Recruiting: Study Start: November 12, 2024 : Primary Completion: Webb13 jan. 2024 · A low-key research collaboration struck a year ago has led to Merck & Co today taking out an exclusive licence to an anticancer project targeting the Kras …
Webb1 nov. 2024 · Here, we report the discovery of IACS-13909, a specific and potent allosteric inhibitor of SHP2, that suppresses signaling through the MAPK pathway. IACS-13909 … WebbBBP-398 (IACS-15509 / IACS-13909) Navire (Bridgebio Pharma) Ph1 started Nov 2024 ERAS-601 Erasca Ph1 (Flagshp-1) started Dec 2024 SH3809 Nanjing Sanhome Ph1 …
Webb10 maj 2024 · March 21, 2024 updated by: Navire Pharma Inc., a BridgeBio company A Phase 1 Study of the SHP2 Inhibitor BBP-398 (Formerly Known as IACS-15509) in Combination With the Programmed Death Receptor-1 Blocking Antibody Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation Webb27 juli 2024 · SHP2 抑制剂 BBP-398（以前称为 IACS-15509）在晚期实体瘤患者中的 1/1B 期首次人体研究. 一项评估安全性、耐受性和最大耐受剂量 (MTD) 并确定 BBP-398（ …
WebbNavire Pharma Developing SHP2 Inhibitors To Treat Cancer
Webb3 nov. 2024 · In EGFR-mutant osimertinib-resistant NSCLC models with EGFR-dependent and EGFR-independent resistance mechanisms, IACS-13909, administered as a single … thomas hogarth lawyer amherstburgWebbBBP-398 (Formerly Known as IACS-15509) for Solid Tumors BBP-671 for Organic Acidemia TAS2940 for Breast Cancer ZX-4081 for Solid Tumors for Solid Tumors for Colorectal Cancer TP-1287 for Sarcoma for Solid Tumors for Canavan Disease for Lung Metastasis for Solid Tumors for Colorectal Cancer for Non-Small Cell Lung Cancer ugly freddyWebbBBP-398 (Formerly Known as IACS-15509) 1. Seltorexant. 1. Fulvestrant Run-In. Study Objectives. 1 Primary · 0 Secondary · Reporting Duration: 6 days of wear. 6 days of wear. Lens Handling on Removal. Trial Safety. Safety Progress. 1 of 3. Similar Trials. 1. BBP-398 (Formerly Known as IACS-15509) 1. Seltorexant. 2. thomas hogan attorney modesto caWebbInternational Association of Classification Societies (IACS) är en icke-statlig internationell organisation med tolv stora klassningssällskap som medlemmar. Sjöfartsklassning avser att främja säkerhet till liv, egendom och miljö genom att etablera regler och verifiera tillämpningen av dessa beträffande teknisk standard för formgivning, … ugly freddy fnafWebb16 maj 2024 · The primary objective for Phase 1a Dose Escalation is to evaluate the safety, tolerability, and RP2D of BBP-398, a SHP2 inhibitor, when used in combination … ugly freedomsWebbIn EGFR-mutant osimertinib-resistant NSCLC models with EGFR-dependent and EGFR-independent resistance mechanisms, IACS-13909, administered as a single agent or in combination with osimertinib, potently suppressed tumor cell proliferation in vitro and caused tumor regression in vivo. ugly fountainthomas hogeling